Ramucirumab: Boon or bane.
Ramucirumab is the recent addition to the list of monoclonal antibodies being tried in various malignancies. It has been approved in non-small cell lung cancer, gastric cancer and colorectal cancer after progression of one or more lines of therapies in the advanced setting. Though randomized trials have shown benefit, cost effectiveness is questionable. Moreover, the benefits shown are marginal, putting a question mark over its clinical usage. This review summarizes the latest evidence on ramucirumab.